This discrepancy may be explained by the protective effects of bevacizumab (anti-VEGF) on hepatic sinusoids, reducing portal vascular resistance in patients treated with oxaliplatin and lowering the risks of intraoperative bleeding and portal hypertension-related ascites, as previously reported [24,25,26,27]. This evidence concerns the gene VEGFA and liver disorder.